Onkologie 2020: 14(Suppl.D): 85-88 | DOI: 10.36290/xon.2020.046

A case of fairly advanced metastatic BRAF-mutated malignant melanoma treated with pembrolizumab with an excellent therapeutic response

David Šulc
Onkologické oddělení Masarykovy nemocnice, Krajská zdravotní, a. s., Ústí nad Labem

The article deals with the issue of first-line treatment of metastatic BRAF-mutated malignant melanoma in a female patient with fairly advanced disease and significant comorbidities. The case report describes practical experience with an excellent and rapid response to treatment with pembrolizumab.

Keywords: metastatic malignant melanoma, BRAF mutation, pembrolizumab.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šulc D. A case of fairly advanced metastatic BRAF-mutated malignant melanoma treated with pembrolizumab with an excellent therapeutic response. Onkologie. 2020;14(Suppl.D / Onkologické kazuistiky 3):85-88. doi: 10.36290/xon.2020.046.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Robert C, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma (KEYNOTE-006 trial), N Engl J Med 2015; 372: 2521-2532. Go to original source... Go to PubMed...
    2. James Larkin FRCP, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2019; 381: 1535-1546. Go to original source... Go to PubMed...
    3. Schadendorf D, Long GV, Stroiakovski D, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer 2017; 82: 45-55. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.